Clinical trial registry record

A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated March 13, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05811351
Last registry update
March 13, 2026
Status
Completed
Phase
Phase 2
Sponsor
Janssen Research & Development, LLC
Enrollment
305
Countries
United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
305
Population
ALL · 60 Years
Duration
2023-03-06 to 2026-02-23
Intervention
JNJ-81201887; Prednisone; Placebo; Triamcinolone; Sham Procedure
Comparator
Not reported
Outcomes measured
Global: Change From Baseline in Square Root of Geographic Atrophy (GA) Lesion Area in the Study Eye at Month 18 — Basel…; United States (U.S.) Specific: Rate of Change in Untransformed GA Lesion Area in the Study Eye — Baseline to Month 18; Change From Baseline in Low Luminance Visual Acuity (LLVA) at Month 18 — Baseline and Month 18; Change From Baseline in Reading Speed at Month 18 — Baseline and Month 18; Change From Baseline in Retinal Sensitivity by Mesopic Microperimetry (MAIA) at Month 18 — Baseline and Month 18; Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 18 — Baseline and Month 18; Change From Baseline in Functional Reading Independence (FRI) Index at Month 18 — Baseline and Month 18; Change From Baseline in National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ-25) Composite Score at Mont…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 80%Title contains controlled term: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON